Medical AI, a medical artificial intelligence company, has secured strategic investment from Naver.
With this investment, Medical AI plans to participate as a key partner in Naver's ongoing expansion of the healthcare ecosystem and pursue various joint projects. Naver has recently expanded its healthcare business with a series of investments in clinical trial platform companies, body composition analysis companies, and cloud-based electronic medical records companies.
Medical AI, a medical AI company founded in 2019 by CEO Kwon Jun-myung, a graduate of Seoul National University College of Medicine, focuses on developing AI technology that analyzes electrocardiograms (ECGs), which record the heart's electrical signals. Its technological uniqueness lies in its ability to detect functional and structural heart conditions, such as heart failure, early through AI analysis, which has been difficult to detect with conventional ECG tests.
Last year, the company was recognized for its technological prowess when it was selected as the first national strategic technology in the medical AI field. Recently, in a technology assessment for special listing under the technology special listing system, the company received an A grade from both evaluation agencies, and is currently pursuing a super-gap technology special listing system in the second half of the year.
Medical AI was the first in the world to commercialize AiTiALVSD, a medical device software that aids in the diagnosis of heart failure based on electrocardiograms. The solution is being used in 236 medical institutions worldwide, with over 2 million cumulative users and 140,000 monthly paying users.
A recent comparative study of accuracy presented at the European Society of Cardiology by the University Hospital of Amsterdam in the Netherlands reported that AiTiALVSD recorded the highest accuracy, beating out major competing models from the United States and Europe.
Medical AI also received the world's first approval for its medical device software, AiTiALVSD-1L, which utilizes electrocardiogram data measured by a wearable device to aid in the diagnosis of heart failure. This product, developed in collaboration with Samsung Electronics, is expanding its application beyond hospital-centric healthcare settings into everyday life.
Going forward, Medical AI and Naver plan to continue their collaboration, focusing on expanding the platform for AI-based disease diagnosis technology, developing services utilizing everyday health data, and expanding the practical use of medical AI technology.
Medical AI CEO Kwon Jun-myeong announced that the company plans to expand its role in the healthcare ecosystem based on biosignal data analysis technology through collaboration with Naver.
- See more related articles
You must be logged in to post a comment.